A regulatory ban on Silimed silicone implants could lead to consumers claiming for compensation if the same contaminants of the Brazilian manufacturing plant are also detected in Europe.
Earlier this month, the Medicines and Healthcare Products Regulatory Agency (MHRA) suspended sales of the implants after it was announced that contaminants were detected in Silimed’s manufacturing facility in Rio de Janeiro. The MHRA, along with other European regulatory bodies, are already testing the implants to determine whether or not the contamination is recent enough not to have impacted previous shipments or if the quality of imported implants has been affected. Until the investigation has been concluded, UK healthcare providers have been advised by the MHRA not to utilise the Brazilian implants.
Though the suspension of sales may ultimately be unnecessary, the act does not come long after the body was criticised by the Commons Health Committee in 2012 for its failings in handling the Poly Implant Prothèse (PIP) implants scandal – where it was discovered that the company were not using medical grade silicone, leading to the imprisonment of the PIP president, Jean-Claude Mas.
As the investigation is still in its early days, no evidence has yet been uncovered that would support a person’s claim for compensation against Silimed, though the MHRA have issued a statement advising those with implants to contact the medical provider where the surgery was carried out.
Though the products are also sold in the United States under Sientra Ltd., manufacturers have stated that any damage should be confined to the European Union, as an ongoing medical trial in the U.S has not shown yet made it public whether or not there are issued with the imported implants.
Those who think that they may be affected by this news should contact their healthcare professional, and if you are subsequently diagnosed with an injury attributable to the faulty implants and wish to make a compensation claim, contact a solicitor. They should be able to provide you with updates of the ongoing investigation and notify you about the MHRA’s suspension of sales.